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The counterregulatory response to hypoglycemia,
which restores normal blood glucose levels to ensure
sufficient provision of glucose to the brain, is critical
for survival. To discover underlying brain regulatory
systems, we performed a genetic screen in recombi-
nant inbred mice for quantitative trait loci (QTL) con-
trollingglucagonsecretion in response toneurogluco-
penia. We identified a QTL on the distal part of
chromosome7andcombined thisgenetic information
with transcriptomic analysis of hypothalami. This re-
vealed Fgf15 as the strongest candidate to control
the glucagon response. Fgf15 was expressed by
neurons of the dorsomedial hypothalamus and the
perifornical area. Intracerebroventricular injection of
FGF19, the human ortholog of Fgf15, reduced activa-
tion by neuroglucopenia of dorsal vagal complex neu-
rons, of the parasympathetic nerve, and lowered
glucagon secretion. In contrast, silencing Fgf15 in
the dorsomedial hypothalamus increased neuro-
glucopenia-induced glucagon secretion. These data
identify hypothalamicFgf15asa regulator ofglucagon
secretion.
INTRODUCTION
Glucose is the major source of metabolic energy for the brain.
This requires that homeostatic processes maintain blood
glucose concentration at a minimum of 5 mM to ensure suffi-
cient provision of glucose to the brain (Unger and Orci, 1981).
Specialized glucose sensing cells present in peripheral loca-
tions, such as the hepatoportal vein area, and in the CNS are
activated by hypoglycemia and initiate a counterregulatory
response to normalize glycemia (Chan and Sherwin, 2013; Friz-
zell et al., 1993; Jackson et al., 2000). This response is mediated
by activation of the autonomous nervous system and the hypo-
thalamo-pituitary-adrenal axis, leading to the release in the
bloodstream of glucagon secreted by pancreatic alpha cells,
and of catecholamines and glucocorticoids secreted by theCell Repo
This is an open access article under the CC BY-Nadrenal gland (Verberne et al., 2014). The combined action of
these hormones promotes hepatic glucose production, lipolysis
in the adipose tissue, suppression of insulin secretion, and inhi-
bition of glucose uptake in muscle and fat. These actions restore
normoglycemia and glucose flux to the brain (Verberne et al.,
2014). The counterregulatory response to hypoglycemia is,
thus, essential for survival.
In type 1 and type 2 diabetic patients treated with insulin, the
counterregulatory response to hypoglycemia is progressively
blunted causing occasional hypoglycemia. Antecedent hypo-
glycemic episodes then lead to a progressive loss of the hypo-
glycemia cognitive warning signals and to a reduced hormonal
counterregulatory response. This condition, referred to as hypo-
glycemia associated autonomic failure (HAAF), augments the
risks to develop hypoglycemic episodes of increased severity
and is a major obstacle in the treatment of diabetes with insulin
(Cryer, 2013).
Hypoglycemia detection in the brain occurs within special-
ized brain areas, mainly the hypothalamus and the brainstem
(Marty et al., 2007; Ritter et al., 2011). These brain structures
contain neuron subpopulations activated by an increase or a
fall in extracellular glucose concentrations and which are
referred to as glucose excited (GE) or glucose inhibited (GI) neu-
rons, respectively (Routh, 2002). Identification of these neurons
is based on electrophysiological recording of their firing activity
assessed in acute brain sections or using dispersed neuron
populations. The molecular mechanisms of glucose sensing
by GE or GI neurons are diverse (Thorens, 2012). Glucose
sensing by GE neurons involves proteins also controlling
glucose-induced insulin secretion by pancreatic beta-cells
such asGlut2 (Lamy et al., 2014; Marty et al., 2007), glucokinase
(Levin et al., 2008; Stanley et al., 2013), and the KATP channel
(Evans et al., 2004; Miki et al., 2001). The Na+/glucose co-trans-
porters SGLT1 and SGLT3 may also contribute to glucose
sensing by GE neurons (O’Malley et al., 2006). On the other
hand, AMP-activated protein kinase (AMPK) plays a key role
in activation of GI neurons by hypoglycemia (Alquier et al.,
2007; McCrimmon et al., 2008). In contrast to AMPK and the
KATP channel, which are present in all neurons, Glut2, glucoki-
nase, and the SGLTs are present in specific, only partly overlap-
ping neuronal subpopulations andmay thus be used asmarkers
of glucose-sensing neurons.rts 17, 1795–1806, November 8, 2016 ª 2016 The Author(s). 1795
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identification of glucose sensing cells, in particular, those
implicated in the adaptive response to hypoglycemia is of high
importance to better understand the cause and possible man-
agement of HAAF. So far, the mechanisms of central glucose
sensing have been explored based on the targeted analysis of
genes known to be involved in glucose metabolism or signaling.
Unbiased identification of genes controlling quantitative traits is,
however, possible by screening genetic reference populations.
The BXD recombinant inbred mice, which have been derived
from the cross of DBA/2J and C57Bl6/J mice, form a particularly
useful genetic reference population (Andreux et al., 2012; Ches-
ler et al., 2004; Peirce et al., 2007; Rosen et al., 2007). These
mice have been successfully used to identify genes involved in
various physiological processes such as sleep (Franken et al.,
2001), aging (Houtkooper et al., 2013), blood pressure (Koutni-
kova et al., 2009), or beta-cell function (Wong et al., 2013).
Here, we aimed at identifying genes involved in the counterre-
gulatory response by screening a BXD mouse panel for the
glucagon response to 2-deoxy-D-glucose (2DG)-induced neuro-
glucopenia. This led to the identification of a significant QTL
on the distal part of chromosome 7. To identify the causal
gene in the QTL, we hypothesized that this gene should be
expressed in the hypothalamus, and that its expression
should correlate with the glucagon trait. Combining QTL
analysis and RNA-sequencing (seq) data, we identified hypotha-
lamic Fgf15 as the most likely candidate gene. The functional
involvement of Fgf15was supported by showing that: (1) it is ex-
pressed in dorsomedial hypothalamus and perifornical neurons;
(2) intracerebroventricular (i.c.v.) delivery of FGF19, the human
ortholog of Fgf15, reduced 2DG-induced glucagon secretion
through suppression of dorsal vagal complex neuron activation,
and reduction of parasympathetic nervous activity; and (3)
silencing of Fgf15 in the DMH increased 2DG-induced glucagon
secretion.
RESULTS
Genetic and Genomic Identification of Hypothalamic
Fgf15 as Regulator of Glucagon Secretion
We searched for genomic intervals associated with glucagon
secretion induced by 2DG-induced neuroglucopenia in a panel
of 36 BXD mouse strains. Groups of male mice were generated
for each BXD strain and used when they reached 10 weeks of
age. In a first experimental session, mice were injected intraper-
itoneally (i.p.) with a saline solution and blood was collected
30 min later for plasma preparation and storage. Two weeks
later, the mice received an i.p. injection of 2DG and blood was
collected and plasma prepared. Glucagon levels weremeasured
by radioimmunoassay at the same time for all mice and the ratio
between plasma glucagon after 2DG and NaCl injections was
calculated. This trait varies by 3-fold between BXD strains (Fig-
ure 1A) with the lowest response (1.5-fold) detected in BXD49
and the highest (4.7-fold) in BXD50. This trait was due to differ-
ences in stimulated plasma glucagon levels rather than to differ-
ences in basal glucagonemia (Figure 1B); it was not correlated to
differences in total pancreatic glucagon content across all the
BXD strains (Figure 1C). This suggests that the variability in the
secretion response results from differences in hypoglycemia1796 Cell Reports 17, 1795–1806, November 8, 2016detection and signaling to pancreatic alpha cells rather than
from differences in pancreatic glucagon stores.
Quantitative trait analysis identified a whole genome signifi-
cant QTL at the distal part of the chromosome 7 (Figure 1D).
The likelihood ratio statistic (LRS) peak is centered on marker
rs2304086585 (LRS: 24.679; position: 151.6236Mb) and flanked
by markers c7.loc119 (position: 147.5303 Mb) and rs31652431
(position: 152.4411 Mb) (Figure 1E). This locus is 5 Mb wide
and it contains 128 genes; it explains 49 percent of the variance
of the glucagon trait.
To narrow down the genes within the QTL, which could regu-
late glucagon secretion, we hypothesized, first, that these must
be expressed in the hypothalamus where glucose sensitive neu-
rons are located (Karnani and Burdakov, 2011; Ritter et al., 2011;
Routh, 2010) and, second, that their level of expression must
correlate with the glucagon phenotype, assuming that they are
non-coding polymorphisms. We thus performed transcriptomic
analysis of the hypothalamus from all the BXD strains using
mice that had not undergone QTL screening to avoid a possible
impact of 2DG treatment on gene expression. RNA was ex-
tracted from the hypothalamus of 3–6 mice for each strain and
equal amounts of RNA from each mouse were pooled for tran-
script profiling by RNA sequencing analysis. We found that 65
of the 128 genes present in the Chr7 locus were expressed in
the hypothalamus. The hypothalamic expression level of 11
genes was significantly correlated to the glucagon trait (Table
1). Fgf15 mRNA was the most significantly, and negatively,
correlated to the glucagon phenotype (r = -0.571; p = 2.73 3
10-4) (Table 1). The second gene in this table, which shows a
similar high correlation with the trait as Fgf15 is Gm17685 (r =
0562; p = 3.58 3 104). This encodes a long non-coding
RNA transcribed in reverse orientation from exon 2 of Fgf15,
and its expression is highly correlated with that of Fgf15 (r =
0.824; p = 6.68 3 1010). The correlation with the glucagon trait
of the other nine genes (Table 1) showed at least 10-fold less
significant p values. Furthermore, the Fgf15 gene of the DBA/
2J and C57BL/6 mice encodes the same amino acid sequence,
supporting differential expression of this gene as a possible un-
derlying cause of the glucagon trait. We thus selected to further
investigate Fgf15 expression in the hypothalamus and its role in
the response to neuroglucopenia.
Hypothalamic Fgf15 Expression, Parasympathetic
Activity, and Glucagon Secretion
Quantitative analysis of Fgf15 expression in different brain nuclei
showed highest expression in the hypothalamus (average cycle
threshold [CT] of 28.7) and lower expression in the hippocam-
pus, thalamus, and brainstem, with almost undetectable levels
in the cerebellum and cortex (average CTs of 29.6, 30.1, 30.1,
34.2, and 34.5, respectively) (Figure 2A). Brain expression of
Fgf15was, however, much lower than its expression in the ileum,
its major site of expression (average CT of 21.1) (Figure 2A) (Ina-
gaki et al., 2005). Expression of the Fgf15 receptors Fgfr1c,
Fgfr4, and of the co-receptor Klotho beta was found in all brain
regions (Figures 2B–2D).
To determine the site of Fgf15 expression, we performed
in situ hybridization analysis on hypothalamic sections. As
shown in Figures 2E–2I, Fgf15 expression was found mainly in
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Figure 1. A Locus on Chromosome 7 Controls Neuroglucopenia-Induced Glucagon Secretion
(A) Distribution of the glucagon ratio (2DG/NaCl) phenotype in the 36 BXD strains (n = 4–14 for each strain).
(B) Basal and neuroglucopenia-stimulated glucagonemia in the 36 BXD mouse strains. Each circle is the mean glucagonemia for each strain.
(C) Scatterplot representing the absence of correlation between the glucagon ratio (2DG/NaCl) phenotype and the total pancreatic glucagon content in BXDmice.
(D) Whole genome significant QTL on distal chromosome 7. The red line indicates the whole genome significative threshold (p% 0.05). The blue line indicates the
whole genome suggestive threshold (p% 0.63).
(E) Localization of the locus between with a LRS peak on marker rs2304086585.the perifornical area (PeF; Figure 2E) and the dorsomedial hypo-
thalamus (DMH; Figure 2G). In situ hybridization using a con-
trol probe derived from a bacterial gene, DapB, showed no
staining (Figure 2H). No Fgf15 transcripts were detected in the
dorsal vagal complex of the brainstem (Figure 2I). Detection of
Fgf15 in illeal villi is shown for comparison (Figure 2J). Finally,
double in situ hybridization of Fgf15 and of the neuronal marker
NeuN showed that Fgf15 was expressed in neurons (Figures 2K
and 2L).
To verify that Fgf15 could regulate glucagon secretion through
a central mechanism of action, we injected C57BL/6 mice i.c.v.
with FGF19 (the human ortholog of Fgf15, which shows high sta-
bility in vivo and activates the same receptors; Owen et al., 2015)
or an artificial cerebrospinal fluid (aCSF). Sixty min later, themice
received an i.p. injection of saline or 2DG. The glycemia was not
modified by i.c.v. injections of aCSF or FGF19 (Figure 3A; t = 0)
and was similarly increased 30 min after i.p. 2DG injection in
both groups of mice (Figure 3A). The plasma glucagon level in
i.p. saline injected mice was unaffected by previous i.c.v.FGF19 injection (Figure 3B). However, following 2DG-induced
neuroglucopenia, the glucagon response was markedly lower
in mice previously treated with i.c.v. FGF19 (Figure 3B). In these
experiments, secretion of insulin, corticosterone, and epineph-
rine 30 min after i.p. saline or 2DG injections was not affected
by previous i.c.v. FGF19 injection (Figures 3C–3E).
Next, we assessed hypothalamic Fgf15 expression and 2DG-
induced glucagon secretion in normal chow (NC) or high fat diet
(HFD) fedmice, which show altered glucagon plasma levels (Bur-
celin et al., 2002). Mice fed a HFD for 4 weeks showed increased
hypothalamic expression of Fgf15 compared to NC fed mice
(Figure 3F). When injected with 2DG, NC and HFD mice showed
the same hyperglycemic response (Figure 3G). The basal gluca-
gonemia of both groups of mice were the same, but the plasma
glucagon response to 2DG was markedly reduced in HFD fed
mice (Figure 3H). Thus, HFD feeding increased hypothalamic
Fgf15 expression and is correlated with reduced neuroglucope-
nia-induced glucagon secretion in agreement with the results of
the genetic screen.Cell Reports 17, 1795–1806, November 8, 2016 1797
Table 1. QTL Genes Expressed in the Hypothalamus and Correlated with the Glucagon Trait
Genea Start Strand Length Gene ID NM ID rb p Valuec
Fgf15 152.082436 + 4.42 14170 NM_008003 0.571 2.73 3 104
Gm17685 152.080465  2.902 NA 0.562 3.58 3 104
Ccnd1 152.115835 + 9.995 12443 NM_007631 0.472 0.00369
Ppfia1 151.66266  76.975 233977 NM_001195086 0.457 0.00509
Dhcr7 151.009071  25.244 13360 NM_007856 0.456 0.00520
Cttn 151.621628  35.018 13043 NM_007803 0.440 0.00726
Kcnq1ot1 150.399016  83.437 63830 AK041889 0.415 0.0119
Slc22a18 150.659659 + 25.578 18400 NM_001042760 0.401 0.0153
Lrdd 148.624413  4.841 57913 NM_022654 0.379 0.0228
Ifitm1 148.153327 + 2.399 68713 NM_001112715 0.332 0.0482
Tmem80 148.514028  9.026 71448 NM_027797 0.331 0.0488
aGenes are listed according to the p value of the correlation between gene expression and the glucagon trait.
br: Pearson’s correlation coefficient between gene expression and the glucagon trait.
cp value: p value of the Pearson’s correlation between gene expression and the glucagon trait.To more directly determine whether the level of expression of
Fgf15 in the hypothalamus regulates glucagon secretion, we
developed recombinant lentiviruses to express a control or an
Fgf15-specific short hairpin (sh)RNA. Three shRNAs were de-
signed to target the Fgf15 sequence and were subcloned in
lentiviral vectors. These were first tested in HEK293T cells co-
transfected with an Fgf15-GFP expression plasmid. One vector
induced efficient silencing of Fgf15 mRNA and protein expres-
sion (Figures 4A–4C). This was used to generate a recombinant
lentivirus, which effectively silenced Fgf15 expression in trans-
duction experiments (Figure 4D). This or a control lentivirus
was then injected bilaterally in the DMH (Figure 4E). Two weeks
later, the mice were injected i.p. with 2DG and plasma glucagon
was measured 30 min later. The mice were then killed to verify
the sites of virus injection. No difference in basal glycemia or in
glycemic response to 2DG injection was observed between the
two groups of mice (Figure 4F). However, neuroglucopenia-
induced glucagon secretion was significantly increased (22%)
in mice with correct bilateral DMH injection of the silencing lenti-
virus as compared to mice injected with the control lentivirus
(Figure 4G) or mice injected with Fgf15-specific shRNA lentivirus
outside of the DMH (Figure 4G, ‘‘missed’’). Bilateral injection of
the silencing lentivirus in the PeF (Figure 4H) did not impact
glycemia before and 30 min after i.p. 2DG (Figure 4I), nor the
neuroglucopenia-induced glucagon secretion (Figure 4H). Taken
together, these data show that Fgf15 expression by DMH
neurons has a negative impact on neuroglucopenia-induced
glucagon secretion.
Glucagon secretion during hypoglycemia is triggered by the
activation of both parasympathetic and sympathetic branches
of the autonomic nervous system (ANS) (Taborsky and Mun-
dinger, 2012). As i.c.v. FGF19 decreased the glucagon response
to 2DG-induced neuroglucopenia, but had no effect in non-in-
jected or i.p. saline injected mice, we measured sympathetic
and parasympathetic nerve activities in response to i.p. 2DG in
mice, which had previously received i.c.v. aCSF or FGF19. Para-
sympathetic nerve activity showed no differences between
groups in the basal state (Figure 5A). After 2DG injection, its1798 Cell Reports 17, 1795–1806, November 8, 2016activity increased 2-fold in mice pre-treated with aCSF, but re-
mained unchanged in mice pre-treated with FGF19 (Figure 5A).
Sympathetic nerve activity showed no differences between the
groups in the basal state or following 2DG injections (Figure 5B).
Thus, i.c.v. injection of FGF19 inhibits 2DG-induced parasympa-
thetic, but not sympathetic nervous activity.
The dorsal motor nucleus of the vagus (DMNX) is formed by
the soma of the vagal neurons and is controlled by inputs from
several brainstem and hypothalamic nuclei (Berthoud et al.,
1990; Steinbusch et al., 2015). To investigate whether FGF19 in-
fluences these neurons directly or indirectly, we quantified the
number of pERK1/2 (activated by FGF19 binding to its receptor)
positive cells in the hypothalamus and the brainstem 30min after
i.c.v. aCSF or FGF19 injections. We observed an increased num-
ber of pERK1/2 positive cells in the arcuate nucleus (ARC) after
i.c.v. FGF19 injection (Figures 5C and 5D). No increase in
pERK1/2 positive cells was observed in other hypothalamic
nuclei, in the dorsal vagal complex (DVC, which comprises the
DMNX, the nucleus tractus solitarius [NTS], and the area post-
rema [AP]), nor in other brainstem areas. These results are
consistent with a previous study (Marcelin et al., 2013) and sug-
gest that the primary neurons involved in the effect of FGF19 are
located within the ARC.
To determine whether FGF19 could control vagal neurons
of the DVC in an indirect manner, we injected mice i.c.v.
with aCSF or FGF19 and 1 hr later i.p. with NaCl or 2DG. Thirty
min later, the mice were killed and brain sections prepared for
c-fos expression analysis by in situ hybridization. Figures 5E
and 5F show that i.p. 2DG induced a strong increase in c-fos
expression in the NTS and the DMNX. However, in mice, which
had previously received FGF19, 2DG-induced c-fos expression
was markedly lower in both structures.
These data further support a role for central Fgf15 in modu-
lating the sensitivity of the DVC to 2DG-induced neuroglucope-
nia and in reducing the stimulation of vagal activity. They also
support a role of Fgf15 neurons in controlling the DVC through
an indirect mechanism that first controls arcuate neurons
activity.
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Figure 2. Fgf15 Expression in Adult CNS
(A–D) Expression level of Fgf15, Fgfr1c, Fgfr4, and Klotho beta in different brain structures and the ileum (n = 6–8). hypothalamus, Hy; hippocampus, Hip;
thalamus, Th; cerebellum, Cb; brainstem, Bs; cortex, Cx; ileum, Il.
(E–J) In situ hybridization detection of Fgf15 (red signal).
(E–J) PeF; representative section of hypothalamus at bregma1.94mm (F); DMH (G); negative control in PeF usingDapB probes (H); brainstemwith central canal
(CC) DMNX and nucleus of the solitary tract (NTS) (I); and illeal villi (J). The scale bar represents 50 mm.
(K and L) Double in situ hybridization of Fgf15 (green dots) and NeuN (red dots) in PeF and DMH showing neuronal expression of Fgf15. The scale bar represents
10 mm. The data are shown as mean ± SEM.DISCUSSION
The present unbiased approach identified hypothalamic Fgf15 as
a negative regulator of glucagon secretion in response to neuro-glucopenia. In situ hybridization revealed that Fgf15 is expressed
by a subgroup of neurons of the DMH and PeF. Physiological
studies showed that i.c.v. injection of FGF19 reduced, whereas
shRNA mediated silencing of Fgf15 in the DMH increasedCell Reports 17, 1795–1806, November 8, 2016 1799
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Figure 3. Fgf19 and the Control of Glucagon Secretion
(A) Glycemia of mice injected i.c.v. with aCSF or FGF19 60 min before i.p. injection (0 min) of 2DG (600 mg/kg) (n = 7).
(B) Plasma glucagon 30 min after i.p. injection of saline or 2DG in mice that were treated 60 min before with i.c.v. injection of aCSF or FGF19 (n = 7).
(C–E) Plasma insulin (C), corticosterone (D), and epinephrine (E) 30 min after i.p. injection of saline or 2DG in mice that were treated 60 min before with i.c.v.
injection of aCSF or FGF19 (n = 9–10) (E).
(F) Hypothalamic expression of Fgf15 in C57Bl6/J mice fed a NC or a HFD for 4 weeks (n = 6–8).
(G) Glycemia in NC and HFD fed mice before and 30 min after i.p. injection of 2DG (n = 6–8).
(H) Plasma glucagon in NC and HFD fed mice in the basal state and 30 min after 2DG injection (n = 6–8).
Data are mean ± SEM. *p% 0.05 and ***p% 0.001. Two-way ANOVA followed by Bonferroni post hoc test (A–E, G, and H). Student’s t test (F).neuroglucopenia-induced glucagon secretion. Furthermore, i.c.v.
delivery of FGF19 prevented the increase in vagal activity induced
by neuroglucopenia, and this was associatedwith a reduced acti-
vation of DVC neurons. As i.c.v. FGF19 activates pERK1/2 only in
hypothalamic ARC neurons, our data suggest that hypothalamic
Fgf15 modulates DVC activity in an indirect manner.
Fgf15/19 belongs to the endocrine fibroblast growth factor
family, which also includes Fgf21 and Fgf23 (Owen et al.,
2015). Fgf15/19 expression in ileal cells is induced by the bile
acids released in the intestinal lumen in the postprandial state
through activation of the bile acid nuclear receptor FXR (Inagaki
et al., 2005). Fgf15/19 binds to receptors consisting of Fgfr1c or
Fgfr4 and the co-receptor klotho-beta (Owen et al., 2015). In
liver, Ffg15/19 reduces bile acid synthesis through the inhibition1800 Cell Reports 17, 1795–1806, November 8, 2016of Cyp7a1 (Jung et al., 2007; Vergnes et al., 2013). It also induces
glycogen synthesis through the activation of the Ras-Erk-
p90RSK and inhibits gluconeogenesis via the CREB-PGC1a
pathway (Kir et al., 2011; Potthoff et al., 2011). Ffg15/19 has
more recently been described to affect body weight, glucose
tolerance, and insulin sensitivity through a central action (Marce-
lin et al., 2013; Morton et al., 2013; Ryan et al., 2013).
Here, we found that Fgf15 is also expressed in the hypothala-
mus through an unbiased search for genetic intervals associated
with neuroglucopenia-induced glucagon secretion in recombi-
nant inbred mice. Among the 128 genes present in the identified
QTL of chromosome 7, RNA-seq analysis revealed that 11 of
these genes were expressed in the hypothalamus and expres-
sion of Fgf15, and, of the large intergenic noncoding RNA (linc)
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Figure 4. Fgf15 Silencing in the DMH Increases 2DG-Induced Glucagon Secretion
(A) Silencing of Fgf15 expression after co-transfection of HEK293T cells of an Fg15-GFP cDNA with the selected Fgf15-specific shRNA encoding lentiviral vector
(n = 3).
(B) Quantification of Fgf15 protein expression in the same conditions as (A) (n = 3).
(C) Western blot analysis of Fgf15 and b-actin expression quantitated in (B).
(D) Western blot analysis of Fgf15 and b-actin expression in HEK293T cells infected with a control (scrambled) or an Fgf15-shRNA lentivirus and transfected with
an Fgf15-GFP expression plasmid.
(E) Example of the correct bilateral injection in the DMH of Fgf15-shRNA lentiviruses. The scale bar represents 100 mm.
(F) Glycemia in mice injected in the DMH with control (scrambled) or Fgf15-shRNA lentiviruses before (0 min) and 30 min after i.p. injection of 2DG. missed: mice
with incorrect Fgf15-shRNA encoding lentivirus injection sites. (n = 10–19).
(G) Plasma glucagon levels 30 min after 2DG i.p. injections (n = 10–19).
(H) Example of the correct bilateral injection in the PeF of Fgf15-shRNA lentiviruses. The scale bar represents 100 mm.
(I) Glycemia in mice injected in the PeF with control (scrambled) or Fgf15-shRNA lentiviruses before and 30 min after i.p. injection of 2DG (n = 12).
(J) Plasma glucagon levels 30 min after 2DG i.p. injections (n = 12).
Data aremean ±SEM. *p% 0.05; **p% 0.01; and ***p% 0.001. Student’s t test (A, B, and J). Two-way ANOVA followed by Bonferroni post hoc test (F and I). One-
way ANOVA followed by Bonferroni post hoc test (G).RNA-encoding, Gm17685 showed the highest correlation with
the glucagon trait. Expression levels of Fgf15 and Gm17685
were also highly positively correlated to each other. As lincRNAs
are implicated in the control of gene expression through a variety
of mechanisms (Zhao and Lin, 2015), it could be hypothesized
that Gm17685 plays a regulatory role in Fgf15 expression.
Testing this will, however, require future investigations.
To localize Fgf15 expression in the brain, we used a highly sen-
sitive and specific in situ hybridization technique. In the hypo-
thalamus, expression of Fgf15 was found in the PeF and in the
DMH, and co-in situ hybridization analysis with the neuronalmarker NeuN revealed that it was expressed in neurons. No
signal for Fgf15 was identified in the DVC or in any other brain-
stem nuclei.
To assess whether central Fgf15 could impact neuroglucope-
nia-induced glucagon secretion, we first injected i.c.v. FGF19 in
C57BL/6 mice and tested the glucagon response to a subse-
quent i.p. injection of 2DG. We observed that i.c.v. FGF19
decreased the glucagon response induced by 2DG, in agree-
ment with the results of the genetic screen. We also observed
in a model of high fat diet feeding an association between
overexpression of hypothalamic Fgf15 and a decrease inCell Reports 17, 1795–1806, November 8, 2016 1801
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Figure 5. FGF19 Blunts 2DG-Induced Para-
sympathetic Nerve Activity
(A) Parasympathetic nerve firing rate in the basal
state and following i.p. 2DG injection in mice pre-
viously treated with i.c.v. aCSF or FGF19 (top:
representative trace and bottom: quantification of
the firing activity) (n = 6–7).
(B) Sympathetic nerve firing rate in the basal state
and following i.p. 2DG injection in mice previously
treated with i.c.v. aCSF or FGF19 (top: represen-
tative trace and bottom: quantification of the firing
activity) (n = 7).
(C) Representative micrographs of pERK1/2 posi-
tive cells in the ARC 30 min after i.c.v. injection of
aCSF or FGF19.
(D) Quantification of pERK1/2 positive cells in the
ARC 30 min after i.c.v. injection of aCSF or FGF19.
(n = 5–7).
(E) Representative micrographs of c-fos positive
cells in NTS and DMNX at bregma 7.56 mm of
mice that received i.c.v. aCSF and 60 min later i.p.
NaCl (upper), i.c.v. aCSF and 60 min later i.p. 2DG
(mid), or i.c.v FGF19 and 60 in later i.p. 2DG
(lower). area postrema, AP; central canal, CC;
nucleus of the solitary tract, NTS; DMNX.
(F) Quantification of c-fos positive cells in NTS and
DMNX of mice treated as in (E). The scale bar
represents 50 mm.
Two-way ANOVA followed by Bonferroni post hoc
test (A and B). Student’s t test (D). One-way
ANOVA followed by Bonferroni post hoc test (F).
*p% 0.05; **p% 0.01; and ***p% 0.001.
Data are mean ± SEM.2DG-induced glucagon secretion, lending further support to the
negative correlation between hypothalamic Fgf15 and glucagon
secretion. However, the most convincing evidence for a direct
link between hypothalamic Fgf15 expression and glucagon
secretion comes for the shRNA-mediated silencing of Fgf15.
This effect was observedwhen injection of the recombinant lenti-
virus was in the DMH, but not in the PeF. Because the PeF is a
rather large structure, it is possible that our injections were not
sufficiently extensive over the entire PeF structure to observe
an effect. Nevertheless, the critical observation is that injection
of the recombinant lentivirus in the DMH was sufficient to in-
crease 2DG-induced glucagon secretion, establishing a direct
link between Fgf15 in this structure and the control of glucagon
secretion.1802 Cell Reports 17, 1795–1806, November 8, 2016Other studies have shown that i.c.v.
FGF19 could improve glucose tolerance
in HFD fedmice and ob/obmice (Marcelin
et al., 2013; Morton et al., 2013). In ob/ob
mice, theeffect of FGF19onglucose toler-
ance was associated with an increase
in insulin-independent glucose disposal
and insulin sensitivity without changes
in insulin secretion. Glucagon secretion
was, however, only assessed following
i.p. injection of FGF19 and was not modi-
fied by this treatment (Morton et al., 2013).Neuroglucopenia-induced glucagon secretion involves activa-
tion of the parasympathetic and sympathetic branches of the
autonomic nervous system. During graded hypoglycemia devel-
opment, the parasympathetic nerve is activated immediately
when the glycemia falls under the 5 mM and sympathetic
activity is increased at lower glycemic levels (Taborsky and
Mundinger, 2012). Here, we found that i.c.v. FGF19 dampens
parasympathetic, but not sympathetic nerve activity during
2DG-induced neuroglucopenia, an observation that provides
an explanation for the reduced glucagon secretion. Moreover,
the observation that 2DG-induced-glucagon secretion was not
completely blunted after i.c.v. FGF19 can be explained by the
fact that the sympathetic activity was not affected by i.c.v.
FGF19. This suggests that FGF19 specifically impairs the
parasympathetic activity to reduce glucagon secretion during
neuroglucopenia.
The soma of the parasympathetic neurons is located within
the DVC. The primary neurons activated by i.c.v. FGF19 and
identified by immunofluorescence detection of pERK1/2 are,
however, present in the ARC and not found in other hypotha-
lamic or brainstem nuclei. This is in agreement with previous ob-
servations showing that FGF19 activates pERK1/2 in the ARC
(Marcelin et al., 2013). Importantly, we found that i.c.v. FGF19
blunted 2DG-induced neuronal activation in the NTS and the
DMNX as assessed by c-fos expression analysis. This therefore
indicates that i.c.v. FGF19 can prevent activation of DVC neu-
rons in response to neuroglucopenia, and our observations
suggest that its action may be indirect through a first action
on ARC neurons. This also provides an explanation for the
dampening effect of i.c.v. FGF19 on neuroglucopenia-induced
vagal activity.
Previous reports have shown that i.c.v. FGF19 induces
pERK1/2 in NPY/AgRP neurons, but fails to induce c-fos in
POMC neurons (Marcelin et al., 2013; Morton et al., 2013).
Thus, NPY/AgRP neurons could be the primary target
neurons of Fgf15 neurons of PeF and/or DMH, and these
neurons may then negatively control DVC neurons in a
pERK1/2-dependent manner. A role for the ARC and NPY/
AgRP neurons in mediating the effects of Fgf15/19 can be
supported by the fact that the melanocortin pathway has
been shown to be necessary for the central effects of
FGF19 on glucose tolerance (Marcelin et al., 2013; Morton
et al., 2013). Whereas tracing approaches in mice expressing
the Cre recombinase under the control of Fgf15 promoter
should be used to confirm these observations, our data pro-
vide a first insight in a Fgf15-dependent neural network,
which involves an ARC/DVC pathway to regulate glucagon
secretion during neuroglucopenia.
Together, our genetic screen combined with gene expression
analysis provides compelling evidence that hypothalamic Fgf15
is negatively involved in the control by neuroglucopenia of
glucagon secretion. Fgf15 is expressed by discrete subpopula-
tions of neurons in the PeF and DMH and Fgf15/19 blunts vagal
firing activity and dampens the response of the DVC neurons to
2DG-induced neuroglucopenia, a response that involves acti-
vation of pERK1/2 in ARC neurons. Collectively, these results,
initiated by an unbiased search for novel genes involved in
counterregulatory response to neuroglucopenia, reveal a new
site of Fgf15 expression and provide a mechanistic framework
to elucidate Fgf15 action in the control of parasympathetic ner-
vous activity and glucagon secretion. They may provide new
insight into the neuronal control of counterregulation and its
deregulation in the etiology of HAAF in type 1 and type 2 dia-
betic patients.
EXPERIMENTAL PROCEDURES
Mice
BXD mouse strains were purchased from the center of phenogenomics of
EPFL (Lausanne). C57Bl6/J mice were purchased from Charles River Labora-
tories. Animals were housed on a 12 hr light/dark cycle and were fed a stan-
dard rodent chow diet (Diet 3436, Provimi Kliba) or a high-fat diet (235 HF,
SAFE diets). Experiments were performed with 10- to 14-week-old male mice.Study Approval
All animal experimentations were approved by the Veterinary Office of Canton
de Vaud.
Biochemical Measurements
Blood was collected under isoflurane anesthesia. Glycemia wasmeasured us-
ing a glucometer (Ascensia Breeze 2, Bayer Healthcare). Glucagon was quan-
titated by radioimmunoassay (Millipore, cat. number: GL-32K). ELISAs were
used for insulin (cat. number: 10-1247-10, Mercodia), and corticosterone
(cat. number: ADI-900-097, Enzo Life Sciences) measurements. Free plasma
epinephrine was quantified as described (Dunand et al., 2013).
Phenotyping of Glucagon Secretion in BXD Mice
BXD mice were handled daily for 2 weeks before the experiment. On the first
experiment day, glycemia was taken at 9:00 a.m. and, if stable for 1 hr, the
mice received at 10:00 am an i.p. injection of NaCl 0.9%. Blood was collected
30 min later for basal glucagon quantification. Mice were then allowed to
recover for 2 weeks with daily handling. Then the same protocol was used
with i.p. injection of 2DG (600 mg/kg).
RNA-Seq Analysis
Total RNA extraction from hypothalamus and brainstem samples was per-
formed using the peqGOLD TriFast method (PEQLAB). RNA were obtained
from mice sacrificed during the morning in random fed conditions as for the
QTL screening. RNA integrity was verified with a 2100 Bioanalyser (Agilent).
For each BXD strain, equal amounts of RNAs from 3 to 6 hypothalami were
pooled in a final volume of 50 mL. RNA-seq libraries were prepared using
1 mg of pooled RNAs and the Illumina TruSeq Stranded mRNA reagents (Illu-
mina) on a Sciclone liquid handling robot (PerkinElmer) using a PerkinElmer-
developed automated script. Cluster generation was performed with the re-
sulting libraries using the Illumina TruSeq SR Cluster Kit v3 reagents and
sequenced on the Illumina HiSeq 2000 using TruSeq SBS Kit v3 reagents.
Sequencing data were processed using the Illumina Pipeline Software version
1.82. A sequencing depth of 40millions of reads using 100 bp single-end reads
was used. Readsweremapped to themm9 genomewith tophat (v. 2.0.8) using
library-type = fr-firststrand. Other parameters were set by default. Count data
for exons were generated using htseq-count from the HTSeq package (http://
www.huber.embl.de/users/anders/HTSeq/, version 0.5.4p3) using RefSeq
annotation, with parameters stranded = reverse and mode = union. The
normalized read counts per gene were log transformed, and then Pearson cor-
relationwas used to calculate the correlation of gene expression with the phys-
iological trait.
QTL Mapping
GeneNetwork (www.genenetwork.org) variants data set comprising about
15,000 SNPs on the whole mouse genomewas used to performQTLmapping.
Calling SNPs on our RNA-seq data have been used as a way to check for ge-
netic drift in the BXD strains. SNP calling was performed using the Genome
Analysis ToolKit from the Broad Institute (v. 3.2) using the recommended work-
flow for RNA-seq data. Variants were filtered using a quality threshold (> =
5,000). Furthermore, genotypes with more than 10% missing information
were also removed. This allowed tagging the discrepant variants—compared
to our RNASeq experiments—as ‘‘unknown’’ (eight 0.05% genotypes per
strain) for QTL analysis. Finally, variants similar to our SNP calling data were
merged to remove redundant information. For QTL analysis, we used the
r/qtl packages with Haley-Knott (HK) regression method. Pseudo-markers
were generated at a density of 1 cM. QTL location was obtained with 1.5
LOD (6.915 LRS) support intervals as suggested previously (Broman and
Sen, 2009). The significance and suggestive thresholds were computed with
2,000 permutations: the sequences of the various strains were shuffled
2,000 times and association recalculated at each permutation. This allowed
calculating the probability to find these associations by chance.
shRNA Selection and Lentivirus Production
To test the efficiency of the Fgf15 shRNAs, an Fgf15 cDNA was subcloned
in frame with GFP in the pCMV6-AC-GFP plasmid (cat. number: MG202456,
OriGene) and scrambled or Fgf15-targeted shRNAs were subloned in theCell Reports 17, 1795–1806, November 8, 2016 1803
pGFP-C-shLenti plasmid (cat. number: TL514099, OriGene). The vectors
were co-transfected into HEK293T cells using lipofectamine 3000 (cat.
number: L3000015, Thermo Fisher Scientific). At 48 hr later, total RNA
and proteins were extracted and Fgf15 expression was determined by qRT-
PCR and protein by western blot. The selected shRNA sequence has the
following sequence: 50-GTCTGTGTCAGATGAAGATCCACTCTTTC-30. Lenti-
viruses were produced as described (Salmon and Trono, 2006). Viral titers
were evaluated by infection of HEK293T cells. The silencing efficacy of the
Fgf15-shRNA lentivirus was tested in infected HEK293T cells that were trans-
fected with Fgf15 expression plasmid.
Stereotaxy
Surgeries were performed under ketamine/xylazine anesthesia. Cannulas
were placed in the lateral ventricle (0.7 mm from the bregma; 1.3 mm
from the midline; and 1.8 mm from the surface of the skull) (Paxinos and
Watson, 1982). Lentiviruses (200 nL; 4.109 TU/mL) were injected in the DMH
(1.7 mm from the bregma; ± 0.35 mm from the midline; and 5.0 mm from
the surface of the skull) and PeF (1.7 mm from the bregma; ± 0.75 mm
from the midline; and 5.15 mm from the surface of the skull) (Paxinos and
Watson, 1982). Animals were allowed to recover for 1 week with daily handling
and body weight monitoring after i.c.v. placement and for 2 weeks after lenti-
virus injections. The placement of the cannula was checked by histological
analysis after blue ink delivery, and the sites of injection (GFP fluorescence)
were verified on 40 mm brain sections.
I.c.v. Injections
Mice received at 9:00 am on the test day either i.c.v. aCSF (125 mM NaCl,
2.5 mM KCl, 1.25 mMNaH2PO4, 1 mMMgCl2, 2 mMCaCl2, 26 mM NaHCO3
and 12.5 mM sucrose, 300 mOsm, and pH = 7.4) or FGF19 (2.5 mg) (cat. num-
ber: cyt-700-b, Prospecbio). One hr later, mice were injected i.p. with NaCl
0.9% or 2DG 600 mg/kg. Blood and brains were collected 30 min later for
quantification of glucagon secretion or for in situ hybridization detection of
c-fos. For pERK1/2 detection, brains were dissected 30min after i.c.v. delivery
of either aCSF or FGF19.
qRT-PCR
Tissues preparation, RNA extraction, and qRT-PCR were performed as
described (Mounien et al., 2010). The following forward (F) and reverse
(R) primers were used: fibroblast growth factor 15 (Fgf15) F50-GAGGAC
CAAAACGAACGAAATT-30 and R50-ACGTCCTTGATGGCAATCG-30; fibro-
blast growth receptor 1 isoform c (Fgfr1c): F50-GGAGGTGCTTCATCTAC
GGA-30and R50-AGAGTGATGGGAGAGTCCGA-30; fibroblast growth receptor
4 (Fgfr4): F50-GCCCGACAGTTCTCTTTGGA-30 and R50- TTCCCAAAGCGGA
TCGAGAG-30; klotho beta (Klotho beta): F50-CCTTCCCACTGGCAATCT
GT-30and R50-GGGTGGTACAACGTCACCAT-30; and beta-glucuronidase
(Gusb): F50-GTGATGGAGGAGCTGGTTCG-30 and R50-AGCAGAGGAAGGCT
CATTGG-30. Gusb was used as a housekeeping gene to normalize gene
expression in all experiments.
Immunofluorescence Microscopy and In Situ Hybridization
For immunofluorescence detection of pERK1/2, mice were fixed by a trans-
cardiac perfusion of 4% cold paraformaldehyde (PFA) in sodium phosphate
buffer (0.1 M, pH 7.4). Brains were dissected and kept for 2 hr in PFA at 4C
before overnight incubation in sucrose 30% at 4C and frozen at 80C.
There were 20 mm cryosections that were prepared, placed on glass slides,
and incubated in a blocking buffer consisting of 0.1 M phosphate buffer pH
7.4 containing 3% of normal goat serum and 0.3% Triton X-100 for 1 hr, then
with a rabbit monoclonal antibody directed against pERK1/2 (cat. number:
4370, 1/200, Cell Signaling) for 48 hr, and for 1.5 hr with an Alexa Fluor
488-conjugated goat anti-rabbit IgG (H+L) antibody (cat. number: 11008,
1/400, Life Technologies). Slides were mounted in Mowiol for fluorescence
imaging. For pERK1/2 positive cells quantification, four different sections
for each mouse were analyzed. For in situ hybridization analysis, the hypo-
thalamus and brainstem were dissected using a mouse brain matrix with
1-mm section dividers (CellPoint Scientific); all tissues were fixed for 28 hr
in 10% formalin before embedding in paraffin. There were 5 mm sections
that were cut and in situ hybridization for Fgf15, c-fos, NeuN, and dihydrodi-1804 Cell Reports 17, 1795–1806, November 8, 2016picolinate reductase (DapB) (cat. number: 412811, 316921, 313311, and
310043) was processed using the RNAscope and RNAscope 2.0 HD Red
Detection Kit Assay (Advanced Cell Diagnostics). Double in situ hybridization
was performed using RNAscope 2-Plex Assay (cat. number: 320701). Sec-
tions were counterstained with Mayer’s hematoxylin, mounted using Aquatex
mounting medium (cat. number: 363123S, VWR), and observed using an
Axio Imager D1 (Zeiss) microscope interfaced with AxioVision software
(Zeiss). Quantification of c-fos expression was performed on sections cut
at bregma 7.56 mm from three different mice. Image analysis was per-
formed using ImageJ.
Autonomic Nervous System Activity Recording
The firing rates of the thoracic branch of both vagal and sympathetic nerves
along the carotid artery were recorded as previously described (Magnan
et al., 1999; Tarussio et al., 2014). Unipolar nerve activity was recorded contin-
uously for 1 hr under isoflurane anesthesia (30 min during basal condition after
i.c.v. aCSF/FGF19 and before i.p. 2DG and 30min during 2DG-induced neuro-
glucopenia) using the LabChart 8 software (AD Instrument). Data were digi-
tized with PowerLab 16/35 (ADInstruments). Signals were amplified 105 times
and filtered using 200/1,000 Hz band pass filter. Firing rate analysis was per-
formed using LabChart 8.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical analysis were performed using
GraphPad Prism 5.0c, either by a one-way Anova followed by Bonferroni post
hoc test, a two-way Anova followed by Bonferroni post hoc test, or by an un-
paired two-tailed Student’s t test when appropriate. p values less than 0.05
were considered significant.
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